

---

---

---

---

---


---

---

---







## OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results

*Conference call begins at 4:30 p.m. Eastern time today*

**MIAMI (August 7, 2024) – OPKO Health, Inc. (NASDAQ: OPK)** reports business highlights and financial results for the three and six months ended June 30, 2024.

Highlights from the second quarter and recent weeks include the following:

**Enrollment underway in the MDX2001 Phase 1 trial for the treatment of solid tumor cancers.** MDX2001, a tetraspecific antibody, is designed to optimize T-cell function to stimulate tumor regression while minimizing the likelihood of antigen escape. This Phase 1 open-label trial is expected to enroll 45 cancer patients with a variety of solid tumors at six clinical trial sites, and to evaluate safety, tolerability, pharmacokinetics and early evidence of anti-tumor activity.

**The global commercial launch of NGENLA® is ongoing by OPKO's partner, Pfizer. NGENLA has been launched in all major markets.** OPKO is entitled to gross profit sharing based on sales of both NGENLA and Pfizer's daily growth hormone product, Genotropin®. In addition, OPKO is also entitled to a percentage of the net sales of Genotropin® in the United States.

OPKO Health, Inc.  
b

OPKO Health, Inc.  
s art

**Consolidated:** Consolidated total revenues for the second quarter of 2024 were \$182.2 million comp0w



\_\_\_\_\_

\_\_\_\_\_

